^
    1m
    PROSPECTOR: Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1/2, N=152, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    FOLH1 positive
    |
    docetaxel • AZD9574 • FPI-2265
    1m
    Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, Novartis Pharmaceuticals | Phase classification: P1/2 --> P1 | Trial completion date: Nov 2029 --> Mar 2031 | Trial primary completion date: Nov 2026 --> Mar 2031
    Phase classification • Trial completion date • Trial primary completion date
    |
    FOLH1 positive
    2ms
    Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy (clinicaltrials.gov)
    P1/2, N=90, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    Bavencio (avelumab) • peposertib (M3814) • Xofigo (radium Ra-223 dichloride)
    2ms
    Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment (clinicaltrials.gov)
    P1, N=18, Suspended, National Cancer Institute (NCI) | N=30 --> 18
    Enrollment change
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    Actimab-A (lintuzumab-Ac225)
    2ms
    Cancer-associated fibroblast activation protein in Appalachian women with uterine cervix cancer. (PubMed, Front Oncol)
    Cancer-associated fibroblast FAP immunoreactivity in this series indicates that [212Pb]Pb-PSV-359 radiopharmaceutical therapy might have usefulness in women with persistent, recurrent or metastatic uterine cervix cancer. A phase I clinical trial inclusive of metastatic uterine cervix cancer patients is underway (NCT06710756).
    Journal
    |
    FAP (Fibroblast activation protein, alpha)
    2ms
    Impact of ataxia-telangiectasia mutated (ATM) loss on radiobiological and immune response to radium-223 in prostate cancer in vitro models. (PubMed, Clin Transl Radiat Oncol)
    These findings demonstrate that ATM-deficiency enhances radiobiological response and amplifies immune activation to 223Ra, supporting further pre-clinical evaluation of ATM loss as a determinant of response and therapeutic target to optimise 223Ra based strategies for mCRPC.
    Preclinical • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • STING (stimulator of interferon response cGAMP interactor 1) • TP53BP1 (Tumor Protein P53 Binding Protein 1) • IFIT2 (Interferon Induced Protein With Tetratricopeptide Repeats 2)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Xofigo (radium Ra-223 dichloride)
    2ms
    Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Jun 2026 --> Dec 2026
    Trial initiation date • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    IDH1 R132 • IDH wild-type
    |
    Libtayo (cemiplimab-rwlc) • Actimab-A (lintuzumab-Ac225) • Zamyl (lintuzumab)
    2ms
    ETCTN 10302: Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • ER negative
    |
    paclitaxel • Xofigo (radium Ra-223 dichloride)
    2ms
    Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=42, Recruiting, Weill Medical College of Cornell University | N=20 --> 42 | Active, not recruiting --> Recruiting
    Enrollment open • Enrollment change
    |
    CELLSEARCH®
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    2ms
    Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Institut Cancerologie de l'Ouest | Trial completion date: Aug 2028 --> Jan 2030 | Initiation date: Feb 2026 --> Jan 2027 | Trial primary completion date: Aug 2027 --> Jan 2029
    Trial completion date • Trial initiation date • Trial primary completion date • First-in-human
    |
    Rencarex (girentuximab)
    2ms
    Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [225Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor-Expressing, Well-Differentiated GEP-NETs. (PubMed, J Nucl Med)
    The 213Bi daughter mostly remained with DOTATATE in tumors, decaying at the same location as 221Fr. The favorable tumor-to-normal tissue absorbed dose ratio of [225Ac]Ac-DOTATATE supports its use in patients with SSTR-expressing GEP-NETs.
    P1 data • Journal
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    Actinium-225 DOTATATE (RYZ101)
    2ms
    Rad2Nivo: Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=39, Active, not recruiting, University of Utah | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Feb 2025 --> Apr 2026
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    Opdivo (nivolumab) • Xofigo (radium Ra-223 dichloride)